Premium
Comparison of treatment outcomes of childhood Hodgkin lymphoma in two US centers and a center in Recife, Brazil
Author(s) -
Hsu Saunders C.,
Metzger Monika L.,
Hudson Melissa M.,
Pedrosa Francisco,
Lins Mecneide,
Pedrosa Marcia,
Barros Cynthia,
Maciel Kaline,
Pui ChingHon,
Ribeiro Raul C.,
Howard Scott C.
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20883
Subject(s) - medicine , disease , lymphoma , pediatrics , cure rate , cancer , log rank test , survival rate , overall survival , childhood cancer
Abstract Background Pediatric Hodgkin lymphoma (HL) has a cure rate of more than 80% in high‐income countries (HIC). However, more than 80% of the world's children live in low‐income countries (LIC), where the cure rate is often much lower. Procedure We compared the outcome of HL of 371 patients treated at two pediatric oncology centers in the US to that of 62 patients treated at one center in Recife, Brazil (IMIP) to determine whether the same treatment strategy should be used in both high‐income and LIC. The logrank test was used to compare event‐free and overall survival. Results The percentages of patients with unfavorable disease at each center were similar ( P = 0.72). Patients with favorable disease at IMIP had estimated 5‐year survival rates comparable to those of the US centers (100% and 99%, respectively). Among patients with unfavorable disease, those treated at IMIP had a 5‐year event‐free survival (EFS) rate of 60%, compared to 78% at the US centers; ( P = 0.08). The 5‐year survival estimate after relapse was 25% at IMIP versus 61% at the US centers ( P = 0.08). The 5‐year overall survival for patients with unfavorable disease was 72% at IMIP versus 90% at the US centers ( P = 0.01). Conclusions Intensive frontline therapy should be considered for patients with unfavorable HL in LIC where the relapse rate is high and the salvage rate is low, provided that supportive care is adequate. Pediatr Blood Cancer 2007;49:139–144. © 2006 Wiley‐Liss, Inc.